Skip to content

Reducing Aggressive behaviour among People with an Intellectual Disability through Supplementation of Vitamins, Minerals and n-3 Fatty Acids

Reducing Aggressive behaviour among People with an Intellectual Disability through Supplementation of Vitamins, Minerals and n-3 Fatty Acids - Reducing aggression through dietary supplements

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON48658
Enrollment
200
Registered
2019-10-10
Start date
2018-02-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aggression aggressive behaviour

Interventions

The intervention consists of a daily supplementation of 2 multivitamin and mineral capsules "Multi Vital Forte" by Bonusan, supplemented with n-3 fatty acids "Omega 3 forte" in softgel capsules by B
Aggression
intellectual disability

Sponsors

LUMC
Lead Sponsor

Eligibility

Age
12 Years to 64 Years

Inclusion criteria

Inclusion criteria: intellectually disabled (IQ

Exclusion criteria

Exclusion criteria: Pregnancy Breastfeeding People with: Williams syndrom, Wilson's desease, primary hyperparathyroidism and hemochromatosis. Current use of multi vitamins, -minerals and omega-3 fatty acids supplementation and refusal to quit this at least two moths before the beginning of the intervention Allergy for fish The use of the following medication: levothyroxine, methyldopa en levodopa

Design outcomes

Primary

MeasureTime frame
The primary study parameter is the amount of aggressive behavior registered with the Modified Overt Aggression Scale (MOAS).

Secondary

MeasureTime frame
The secondary study parameters are: Aggressive- and anti-social behavior measured by the SDAS. Quality of life measured by IDQOL-16 The cortisol status measured by hair analyses. The micobiome measured with the aid of a feces analysis.

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)